Holen Sie sich die Stockscreener-App
27.47
0.62%
-0.17
Handel nachbörslich:
27.50
0.03
+0.11%
Schlusskurs vom Vortag:
$27.64
Offen:
$27.64
24-Stunden-Volumen:
6.08M
Relative Volume:
0.57
Marktkapitalisierung:
$10.62B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-3.1466
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
-15.89%
1M Leistung:
-9.90%
6M Leistung:
-21.47%
1J Leistung:
-67.20%
1-Tages-Spanne:
$27.30
$27.97
1-Wochen-Bereich:
$26.56
$33.40
52-Wochen-Spanne:
$23.15
$91.99
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.47 | 10.74B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
674.90 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Barclays Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Moderna: RSV Upside Slim, Cash Burn Heavy (NASDAQ:MRNA) - Seeking Alpha
Let’s make a deal? Big Pharma execs express varying views on their M&A future - PharmaVoice
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 - GlobeNewswire Inc.
Zurcher Kantonalbank Zurich Cantonalbank Sells 134,443 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Wealthquest Corp Takes $1.04 Million Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - The Florida Times-Union
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Pocono Record
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Courier-Journal
Moderna Seeks To Be Cleared In $5B COVID Vax Patent Case - Law360
BofA Securities lowers Moderna stock price target to $24 on COVID reliance - Investing.com
EU regulator backs Moderna's updated COVID vaccine - MSN
Moderna Tops Vaccine Expectations But Trims Future Outlook - Finimize
Moderna stock falls as UBS reiterates Buy rating amid cost cuts - Investing.com Canada
How the U.S. mRNA Therapeutics Market Will Evolve by 2032 - openPR.com
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish (MRNA) - Seeking Alpha
Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Has $1.16 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
XTX Topco Ltd Raises Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Banque Cantonale Vaudoise Takes Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What is Moderna Inc. company’s growth strategyPowerful profit generation - Jammu Links News
Private Advisor Group LLC Sells 13,174 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What analysts say about Moderna Inc. stockMaximize your portfolio’s growth potential - jammulinksnews.com
Moderna: Is Now the Time to Buy the Deep Value Dip? - FXEmpire
Moderna’s Hold Rating: Navigating Revenue Adjustments and Product Development Uncertainties - TipRanks
What are Moderna Inc. company’s key revenue driversHigh-octane gains - jammulinksnews.com
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? - Benzinga
When is Moderna Inc. stock expected to show significant growthHigh-octane financial growth - Jammu Links News
Is Moderna Inc. a growth stock or a value stockBuild wealth faster with expert stock selection - Jammu Links News
What institutional investors are buying Moderna Inc. stockUnrivaled growth potential - Jammu Links News
Letko Brosseau & Associates Inc. Has $25.41 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap DownTime to Sell? - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Q2 2025 Earnings Call Transcript - Insider Monkey
Pacer Advisors Inc. Cuts Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Inc (MRNA) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost ... - Yahoo Finance
Moderna Inc (MRNA) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost Reductions and New Approvals - GuruFocus
Moderna’s Q2 2025 Financial Results and Outlook - TipRanks
Moderna Outpaces Losses With Cost Cuts And New Plans - Finimize
Moderna's Q2 Earnings and Strategic Cost Cuts: A Path to Sustainable Recovery? - AInvest
Moderna: Q2 Earnings Snapshot - Norwalk Hour
Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings - Yahoo Finance
Moderna Cuts Outlook And Jobs As Vaccine Sales Wane - Finimize
Moderna, Inc. SEC 10-Q Report - TradingView
Moderna Cuts Forecast, Stock Wobbles Despite Beat - Yahoo Finance
Moderna plans to slash 10% of workforce - The American Bazaar
Moderna Sales Top Estimates As Cost Cuts Bite - Finimize
Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump - Yahoo Finance
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View - TradingView
Moderna cuts sales forecast on UK revenue delay, shares fall - Reuters
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win - Reuters
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):